title: Physical and biological significance of peptide sequences mediating the interaction between high molecular weight kininogen and plasma prekallikrein.
abstract: HK31 (S565-K595) has previously been shown to encompass the binding domain for plasma prekallikrein (PK) within domain 6 of high molecular weight kininogen (HK). The complementary binding domain for HK within PK is mapped to PK56 (F56-G86), in the Apple 1 domain and to PK266 (K266-C295) in the Apple 4 domain. Isothermal titration calorimetry demonstrated that either PK peptide binds to HK31 in 1:1 stoichiometry. Binding of the alternate PK peptide into a ternary complex is facilitated nearly 2-fold. Fluorescence emission spectroscopy revealed that only the binding of PK56 caused a limited decrease in intrinsic tryptophane fluorescence emission intensity of HK31. We conclude that the two PK peptides bind to the HK peptide at different sites. To map the minimal sequence within HK31, truncated new peptides were tested for their ability to compete with HK for binding PK in a cell-free system. D567-T591, a 25-residue peptide which contains sufficient structural information for binding kallikrein in solution, blocked the binding of kallikrein to HK bound to endothelial cells and inhibited PK activation to kallikrein and the generation of kallikrein-activated urokinase on endothelial cell surfaces. HK-derived peptides could modulate excessive fibrinolysis and hypotension in sepsis and multiple trauma.
authors.affiliation: Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA. colman-r@vm.temple.edu
authors.forename: R W
authors.initials: RW
authors.lastname: Colman
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: W Y
authors.initials: WY
authors.lastname: Yan
authors.forename: K R
authors.initials: KR
authors.lastname: McCrae
authors.forename: S S
authors.initials: SS
authors.lastname: Shenoy
authors.forename: R B
authors.initials: RB
authors.lastname: Harris
mesh_terms: D000595:Amino Acid Sequence; D001665:Binding Sites / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D002151:Calorimetry; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism; D005341:Fibrinolysin / Q000096:biosynthesis; D006801:Humans; D007704:Kininogens / Q000097:blood* / Q000737:chemistry; D008969:Molecular Sequence Data; D008970:Molecular Weight; D010452:Peptide Biosynthesis; D010455:Peptides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D010960:Plasminogen Activators / Q000378:metabolism*; D011288:Prekallikrein / Q000737:chemistry / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D013329:Structure-Activity Relationship; D014364:Tryptophan / Q000378:metabolism; D014471:Umbilical Veins / Q000166:cytology / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood*
chemical_list: D001798:Blood Proteins; D007704:Kininogens; D010455:Peptides; D014364:Tryptophan; D011288:Prekallikrein; D010960:Plasminogen Activators; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator